Lunit Inc. (KOSDAQ:328130)

Market Cap	1.21T -13.9%
Revenue (ttm)	83.13B +53.4%
Net Income	-47.39B
EPS	-2,825.47
Shares Out	29.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,773
Average Volume	175,573
Open	40,750
Previous Close	41,200
Day's Range	39,550 - 41,900
52-Week Range	31,800 - 60,700
Beta	1.29
RSI	65.35
Earnings Date	May 14, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a...

• Industry: Software - Application
• Sector: Technology
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 328130

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.